Ameriprise Financial Inc. Has $423,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Ameriprise Financial Inc. lessened its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 93.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,982 shares of the company's stock after selling 454,246 shares during the quarter. Ameriprise Financial Inc.'s holdings in Syndax Pharmaceuticals were worth $423,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. R Squared Ltd bought a new stake in shares of Syndax Pharmaceuticals during the fourth quarter valued at approximately $26,000. Virtus ETF Advisers LLC lifted its holdings in Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after buying an additional 827 shares in the last quarter. Cape Investment Advisory Inc. boosted its position in Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock valued at $85,000 after buying an additional 3,927 shares during the last quarter. KBC Group NV boosted its position in Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company's stock valued at $92,000 after buying an additional 3,559 shares during the last quarter. Finally, Optimize Financial Inc acquired a new stake in shares of Syndax Pharmaceuticals in the 4th quarter valued at $152,000.

Analysts Set New Price Targets

SNDX has been the topic of several research reports. Scotiabank upped their price target on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research note on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Guggenheim reiterated a "buy" rating and set a $32.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. Citigroup dropped their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, Syndax Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $35.91.

Syndax Pharmaceuticals Stock Up 2.6%

NASDAQ SNDX traded up $0.29 during trading on Friday, reaching $11.45. 1,341,835 shares of the stock traded hands, compared to its average volume of 1,791,627. The stock's 50-day moving average price is $11.33 and its 200 day moving average price is $13.29. The firm has a market cap of $985.24 million, a price-to-earnings ratio of -3.15 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.06. The firm had revenue of $20.04 million during the quarter, compared to analyst estimates of $15.88 million. Syndax Pharmaceuticals's quarterly revenue was up 1900.0% on a year-over-year basis. During the same period last year, the firm earned ($0.85) EPS. Analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).